Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 20/20 | 0.75 |
| ▸ | MTOR | P42345 | 19/20 | 0.75 |
| ▸ | PIK3CG | P48736 | 18/20 | 0.75 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Maleic Acid SCHEMBL30442796 | 0.93 | PIK3CA (0.69) | PIK3CAMTORPIK3CGHDAC3 | |
| SCHEMBL2527294 | 0.92 | MTOR (0.79) | PIK3CAMTORPIK3CG | |
| SCHEMBL4317455 | 0.89 | PIK3CA (0.68) | PIK3CAMTORPIK3CGHDAC3 | |
| SCHEMBL1311610 | 0.87 | PIK3CA (0.77) | PIK3CAMTORPIK3CG | |
| SCHEMBL32624 | 0.86 | PIK3CA (0.82) | PIK3CAMTORPIK3CGHDAC3 | |
| SCHEMBL32179 | 0.86 | MTOR (1.00) | PIK3CAMTORPIK3CGHDAC3 | |
| SCHEMBL32474 | 0.85 | PIK3CA (1.00) | PIK3CAMTORPIK3CG | |
| SCHEMBL32189 | 0.85 | MTOR (1.00) | PIK3CAMTORPIK3CG | |
| SCHEMBL12110760 | 0.85 | PIK3CA (0.75) | PIK3CAMTORPIK3CG | |
| SCHEMBL32350 | 0.85 | PIK3CA (0.84) | PIK3CAMTORPIK3CG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112218618-B | Aqueous formulations comprising 1- (4- { [4- (dimethylamino) piperidin-1-yl ] carbonyl } phenyl) -3- [4- (4, 6-dimorpholin-4-yl-1, 3, 5-triazin-2-yl) phenyl ] urea | 辉瑞公司 | 2025-04-04 | — | — | CN | claimed |
| US-20230218628-A1 | PHARMACEUTICAL AQUEOUS FORMULATION COMPRISING 1-(4-{[4-(DIMETHYLAMINO)PIPERIDIN-1-YL]CARBONYL}PHENYL)-3-[4-(4,6-DIMORPHOLIN-4-YL-1,3,5-TRIAZIN-2-YL)PHENYL]UREA | PFIZER LIMITED (GB) | 2023-07-13 | — | — | US | claimed |
| CN-116270452-A | Aqueous preparation | 辉瑞公司 | 2023-06-23 | — | — | CN | claimed |
| US-12600777-B2 | Combination therapies comprising antibody molecules to LAG-3 | NOVARTIS AG (CH) | 2026-04-14 | — | — | US | disclosed |
| US-20260078341-A1 | TREATMENT OF CANCER USING CHIMERIC ANTIGEN RECEPTOR | NOVARTIS AG (CH) | 2026-03-19 | — | — | US | disclosed |
| US-12338287-B2 | Treatment of cancer using a CD33 chimeric antigen receptor | NOVARTIS AG (CH) | 2025-06-24 | — | — | US | disclosed |
| WO-2025096856-A1 | COVALENT CEREBLON LIGANDS | C4 THERAPEUTICS, INC. (US) | 2025-05-08 | — | — | WO | disclosed |
| CN-112218618-B | Aqueous formulations comprising 1- (4- { [4- (dimethylamino) piperidin-1-yl ] carbonyl } phenyl) -3- [4- (4, 6-dimorpholin-4-yl-1, 3, 5-triazin-2-yl) phenyl ] urea | 辉瑞公司 | 2025-04-04 | — | — | CN | disclosed |
| CN-112218618-B | Aqueous formulations comprising 1- (4- { [4- (dimethylamino) piperidin-1-yl ] carbonyl } phenyl) -3- [4- (4, 6-dimorpholin-4-yl-1, 3, 5-triazin-2-yl) phenyl ] urea | 辉瑞公司 | 2025-04-04 | — | — | CN | disclosed |
| CN-112218618-B | Aqueous formulations comprising 1- (4- { [4- (dimethylamino) piperidin-1-yl ] carbonyl } phenyl) -3- [4- (4, 6-dimorpholin-4-yl-1, 3, 5-triazin-2-yl) phenyl ] urea | 辉瑞公司 | 2025-04-04 | — | — | CN | disclosed |
| EP-4416268-A1 | METHODS FOR PRODUCING CARTILAGE AND BONES | Murdoch Children's Research Institute (AU) | 2024-08-21 | — | — | EP | disclosed |
| US-20210212944-A1 | AQUEOUS FORMULATION COMPRISING 1-(4-{[4-(DIMETHYLAMINO)PIPERIDIN-1-YL]CARBONYL}PHENYL)-3-[4-(4,6-DIMORPHOLIN-4-YL-1,3,5-TRIAZIN-2-YL)PHENYL]UREA | PFIZER INC. (US) | 2021-07-15 | — | — | US | disclosed |
| US-10660959-B2 | Formulations of a PI3K/mTOR-inhibitor for intravenous administration | PFIZER INC. (US) | 2020-05-26 | — | — | US | disclosed |
| US-20190105390-A1 | FORMULATIONS OF A PI3K/MTOR-INHIBITOR FOR INTRAVENOUS ADMINISTRATION | PFIZER INC. (US) | 2019-04-11 | — | — | US | disclosed |
| US-10172942-B2 | Formulations of a PI3K/mTor-inhibitor for intravenous administration | PFIZER INC. (US) | 2019-01-08 | — | — | US | disclosed |
| US-20170360935-A1 | FORMULATIONS OF A PI3K/MTOR-INHIBITOR FOR INTRAVENOUS ADMINISTRATION | PFIZER INC. (US) | 2017-12-21 | — | — | US | disclosed |
| WO-2016014553-A1 | SORTASE SYNTHESIZED CHIMERIC ANTIGEN RECEPTORS | NOVARTIS AG (CH) | 2016-01-28 | — | — | WO | disclosed |
| CN-102036995-B | Triazine compounds as inhibitors of PI3 kinase and mTOR | WYETH CORP | 2014-09-17 | — | — | CN | disclosed |
| CN-102036995-A | Triazine compounds as inhibitors of PI3 kinase and mTOR | WYETH CORP | 2011-04-27 | — | — | CN | disclosed |
| WO-2010096619-A1 | PROCESS, PURIFICATION AND CRYSTALLIZATION OF 1-(4-{[4-(DIMETHYLAMINO)PIPERIDIN-1-YL]CARBONYL}PHENYL)-3-[4-(4,6-DIMORPHOLIN-4-YL-1,3,5-TRIAZIN-2-YL)PHENYL]UREA | WYETH LLC (US) | 2010-08-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260078341-A1 | TREATMENT OF CANCER USING CHIMERIC ANTIGEN RECEPTOR | LY96, CD74, EWSR1 | PIK3CA 2999/4885MTOR 4781/4885PIK3CG 2845/4885 |
| US-20210212944-A1 | AQUEOUS FORMULATION COMPRISING 1-(4-{[4-(DIMETHYLAMINO)PIPERIDIN-1-YL]CARBONYL}PHENYL)-3-[4-(4,6-DIMORPHOLIN-4-YL-1,3,5-TRIAZIN-2-YL)PHENYL]UREA | OPRD1, HBZ, SIGMAR1 | PIK3CA 810/4885MTOR 1068/4885PIK3CG 552/4885 |
| US-12600777-B2 | Combination therapies comprising antibody molecules to LAG-3 | IGSF11, IGLV6-57, CD2 | PIK3CA 4568/4885MTOR 4777/4885PIK3CG 4058/4885 |
| US-20230218628-A1 | PHARMACEUTICAL AQUEOUS FORMULATION COMPRISING 1-(4-{[4-(DIMETHYLAMINO)PIPERIDIN-1-YL]CARBONYL}PHENYL)-3-[4-(4,6-DIMORPHOLIN-4-YL-1,3,5-TRIAZIN-2-YL)PHENYL]UREA | CYP2D6, OPRM1, ADRM1 | PIK3CA 2618/4885MTOR 2524/4885PIK3CG 2094/4885 |
| US-10660959-B2 | Formulations of a PI3K/mTOR-inhibitor for intravenous administration | MTOR, RICTOR, PIK3CD | PIK3CA 4/4885MTOR 1/4885PIK3CG 8/4885 |
| US-20170360935-A1 | FORMULATIONS OF A PI3K/MTOR-INHIBITOR FOR INTRAVENOUS ADMINISTRATION | MTOR, RICTOR, PIK3CD | PIK3CA 4/4885MTOR 1/4885PIK3CG 7/4885 |
| US-20190105390-A1 | FORMULATIONS OF A PI3K/MTOR-INHIBITOR FOR INTRAVENOUS ADMINISTRATION | MTOR, RICTOR, PIK3CD | PIK3CA 4/4885MTOR 1/4885PIK3CG 8/4885 |
| US-10172942-B2 | Formulations of a PI3K/mTor-inhibitor for intravenous administration | MTOR, RICTOR, PIK3CD | PIK3CA 4/4885MTOR 1/4885PIK3CG 7/4885 |
| US-12338287-B2 | Treatment of cancer using a CD33 chimeric antigen receptor | CD2, FCGR3B, CD58 | PIK3CA 2700/4885MTOR 4690/4885PIK3CG 2896/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.